To see past surveys click here
Standing Up for America’s Seniors Award
RetireSafe continues to recognize those members of Congress who are not afraid to stand up for America’s seniors. Read more about the award.
RetireSafe, a sponsor at the Florida Conference on Aging, presented a seminar on what's happening in Washington from two different perspectives. Read more...
RetireSafe traveled to Louisville, KY to educate seniors about policy solutions concerning aging in place (AIP) and elder abuse. Read more...
RetireSafe was a sponsor of the National Association of Nutrition and Aging Services Programs conference in San Diego, California. Our focus was highlighting the importance of nutrition in allowing older Americans to age in place.
President Thair Phillips
Click here to see our press release concerning our survey
A couple of weeks ago RetireSafe took a survey of our supporters to find out what they knew about biologics, biosimilars and the safety issues surrounding these new medicines. We found that seniors overwhelmingly support strong patient safeguards for so-called “biosimilar” medications. The survey was taken as federal health officials prepare to release standards for the review and approval of biosimilars—medications that are highly similar but not identical versions of cutting-edge biologic medicines. Biologic medicines treat complex medical conditions, including cancers, autoimmune disorders, and multiple sclerosis.
The survey of 1,467 found that an overwhelming majority of respondents—more than 90 percent—did not know what biosimilar medications were or that the Affordable Care Act enabled the Food and Drug Administration (FDA) to approve the use of biosimilars in the United States. The survey also identified support for patient safety protections, including requiring thorough testing of biosimilars prior to their approval and notification of patients and their physicians whenever a biosimilar is substituted for the original innovator biologic product prescribed.
It is clear that when it comes to new biosimilar drugs, people are rightly concerned and want to keep their drugs safe and effective, so that seniors and other Americans aren’t used as guinea pigs for inadequately tested drugs. Seniors have made their voice clear that patient safety must come first if we are to reap the benefits of new lifesaving medicines.
Among the survey’s key findings:
93 percent did not know that biosimilars cannot be generic versions of biologic drugs—unlike generic versions of chemical drugs that are exact copies;
The survey also found overwhelming support for a strong set of patient safeguards:
Many survey respondents contributed their own thoughts on the significance of requiring strong safety standards to their own health, including:
Given this loud and clear voice RetireSafe is going to be calling on the FDA and elected officials to put in place a series of common-sense safeguards around new medicines in the form of a “Safe Medicines Bill of Rights.” Patient safety must come first if we are to reap the benefits of these new lifesaving medicines. You will hear more from us concerning this important issue.
For the full results of the RetireSafe survey, please click here
For more information on biologics and biosimilars click here
More thoughts from President Phillips...
Will Obamacare leave us with unsafe medicine? Click HERE to find out how this could happen and take our survey.